Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mar 25, 2011 (rev. 1)

Premium

Selventa has selected John Tagliamonte to serve as senior vice president of corporate development.

In his new role, Tagliamonte will work on establishing strategic partnerships with global pharmaceutical and biotechnology companies.

Prior to joining Selventa (formerly GenStruct), Tagliamonte was vice president of business development at Anchor Therapeutics and led strategy and corporate development efforts at ImmunoGen. He has also held positions at Millipore, Laureate Pharma, and Johnson & Johnson.

Tagliamonte earned his BS from Tufts University and an MBA from Boston College.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.